Satishkumar D. Tala

Satishkumar D. Tala

Auto-generated profile, based on publicly available information

Satishkumar D. Tala

Department of Chemistry Atmiya University, Yogidham Gurukul Rajkot Gujarat India

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RCRavi Chaniyara
Ravi Chaniyara
STSatishkumar Tala
Satishkumar Tala
CCChi-Wei Chen
Chi-Wei Chen
XZXiuguo Zang
Xiuguo Zang
RKRajesh Kakadiya
Rajesh Kakadiya
TSTsann-Long Su
Tsann-Long Su

1 July 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RCRavi Chaniyara
Ravi Chaniyara
STSatishkumar Tala
Satishkumar Tala
CCChi-Wei Chen
Chi-Wei Chen
PLPei-Chih Lee
Pei-Chih Lee
RKRajesh Kakadiya
Rajesh Kakadiya
TSTsann-Long Su
Tsann-Long Su

28 July 2009 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
PZParesh Zalavadiya
Paresh Zalavadiya
STSatish Tala
Satish Tala
JAJignesh Akbari
Jignesh Akbari
HJHitendra Joshi
Hitendra Joshi

14 April 2008 in Arkivoc
Verified
Journal Article
Open access
JAJ. D. Akbari
J. D. Akbari
STS. D. Tala
S. D. Tala
MDM. F. Dhaduk
M. F. Dhaduk
HJH. S. Joshi
H. S. Joshi

4 July 2008 in Phosphorus, Sulfur, and Silicon and the Related Elements
Verified
Journal Article
Closed access
JAJ. D. Akbari
J. D. Akbari
PKP. K. Kachhadia
P. K. Kachhadia
STS. D. Tala
S. D. Tala
ABA. H. Bapodra
A. H. Bapodra
MDM. F. Dhaduk
M. F. Dhaduk
SPS. J. Pathak
S. J. Pathak
Some new N-(4-chlorophenyl)-6-methyl-4-aryl-2-thioxo-1,2,3,4-tetrahydro pyrimidine-5-carboxamide 4(a–h) were synthesized by the reaction of N-(4-chlorophenyl)-3-oxobutanamide, thiourea and different aromatic aldehydes. The synthesis of N-(4-chlorophenyl)-7-methyl-5-aryl-2,3-dihydro-5H-thiazolol[3,2-a]pyrimidine-6-carboxamide 5(a–h) was accomplished by cyclocondensation of 1,2,3,4-tetrahydropyrimidine-2-thiones 4(a–h) and 1,2-dibromoethane. The structures of these compounds have been proved by IR, 1H-NMR, and Mass spectral studies. Synthesized compounds 4(a–h) and 5(a–h) were evaluated for their antimicrobial activities. Some of the compounds exhibited significant inhibition on bacterial and fungal growth as compared to standard drugs.

1 April 2016 in Neoplasia
Verified
Journal Article
Open access
CCChi-Wei Chen
Chi-Wei Chen
MWMing-Hsi Wu
Ming-Hsi Wu
YCYi-Fan Chen
Yi-Fan Chen
TYTsai-Yi Yen
Tsai-Yi Yen
YLYi-Wen Lin
Yi-Wen Lin
TLTe-Chang Lee
Te-Chang Lee
The therapeutic effect in non-small cell lung cancer (NSCLC) patients is limited because of intrinsic and acquired resistance. Thus, an unmet need exists for the development of new drugs to improve the therapeutic efficacy in NSCLC patients. In this study, the novel small molecule indolizino[6,7-b]indole derivative BO-1978 was selected to evaluate its therapeutic effects on NSCLC and its preclinical toxicity in animal models. An in vitro cytotoxicity assay revealed that BO-1978 significantly suppressed the growth of various NSCLC cell lines with or without mutations in epidermal growth factor receptor (EGFR). Mechanistically, we demonstrated that BO-1978 exhibited multiple modes of action, including inhibition of topoisomerase I/II and induction of DNA cross-linking. Treatment of NSCLC cells with BO-1978 caused DNA damage, disturbed cell cycle progression, and triggered apoptotic cell death. Furthermore, BO-1978 significantly suppressed the growth of EGFR wild-type and mutant NSCLC tumors in xenograft tumor and orthotopic lung tumor models with negligible body weight loss. The combination of BO-1978 with gefitinib further suppressed EGFR mutant NSCLC cell growth in xenograft tumor and orthotopic lung tumor models. Preclinical toxicity studies showed that BO-1978 administration did not cause apparent toxicity in mice. Based on its significant therapeutic efficacy and low drug toxicity, BO-1978 is a potential therapeutic agent for treatment of NSCLC.